SPH5030 is a Selective and Irreversible HER2 Inhibitor.
2022-09-09
HER2 is a member of the human epidermal growth factor receptor (HER/EGFR/ERBB) family. Importantly, HER2 plays a crucial role in the regulation of cell growth, differentiation, and survival. Specifically, HER2 is the only member in the HER family without a specific ligand, so its overexpression accordingly can lead to cell transformation. In addition, HER2 activation results from heterodimerization with another ERBB member or by homodimerization when HER2 concentrations are high, for instance in cancer.
HER2 gene amplification or overexpression is associated with several solid tumors. So, regulating the cellular signal transduction via inhibition of HER2 is a potent way for tumors. Currently, there are a variety of approved HER2-targeted therapies for the treatment of HER2-positive cancer, such as Trastuzumab, Pertuzumab, Trastuzumab-emtansine (T-DM1), Lapatinib, Tucatinib, Neratinib, and Pyrotinib and so on. Here, we will introduce small-molecule tyrosine kinase inhibitors for HER2-amplified and HER2-mutant cancer treatment.
Keywords
anti-cancer | HER2 | SPH5030
References



